激素序贯疗法和替勃龙在绝经期综合征妇女中的用药保留率调查

doi:10.5246/jcps.2020.09.060

中国药学(英文版) ›› 2020, Vol. 29 ›› Issue (9): 649-655.DOI: 10.5246/jcps.2020.09.060

激素序贯疗法和替勃龙在绝经期综合征妇女中的用药保留率调查

邵淑容^1*, 邵小青², 陈漪¹

1. 宁波市妇女儿童医院药剂科, 浙江宁波 315012
2. 徐州医科大学附属市立医院麻醉科, 江苏徐州 221000

收稿日期:2020-05-18 修回日期:2020-07-24 出版日期:2020-09-30 发布日期:2020-08-19
通讯作者: Tel.: +86-574-83887054, E-mail: shaoshurong1988@163.com
基金资助:
Ningbo Public Welfare Science and Technology Plan (Grant No. 2019C50089).

Study on drug retention in menopausal women with sequential hormone therapy and tibolone

Shurong Shao^1*, Xiaoqing Shao², Yi Chen¹

1. Pharmaceutical department, Ningbo Women and Children’s Hospital, Ningbo 315012, China
2. Anesthesiology Department, the Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou 221000, China

Received:2020-05-18 Revised:2020-07-24 Online:2020-09-30 Published:2020-08-19
Contact: Tel.: +86-574-83887054, E-mail: shaoshurong1988@163.com
Supported by:
Ningbo Public Welfare Science and Technology Plan (Grant No. 2019C50089).

摘要/Abstract

摘要：

本文回顾性分析了我院2015年至2018年四年间诊断为绝经期综合征妇女的用药处方, 比较了雌孕激素序贯疗法和激素连续疗法在绝经期妇女中的用药保留率。应用宁波市妇女儿童医院合理用药管理系统筛选四年间, 诊断为绝经期综合征的处方。在调整年龄、纳入研究的年份以及处方的费用三个系数之后, 应用Kaplan-Meier回归分析比较两种用药方案的处方保留率。两种HRT药物方案在四个年份的分布均呈现逐年增长的趋势, 且两种HRT方案的年龄段均分布在41至60岁之间, 分别占到97.1%和87.06%。另外两种HRT用药方案的单张处方费用的分布大概相同。两种HRT疗法的用药保留率相比, 激素连续方案在4年之内的用药保留率均高于激素序贯方案。且经Kaplan-Meier回归分析, 这种趋势具有显著意义(Tarone-Ware, 卡方值 = 3.857, P = 0.050)。本研究发现,本院为绝经期综合征妇女应用HRT疗法的用药保留时间中位数约为半年的时间, 显著低于以往研究报道的一年或者更长的时间。另外, 本研究发现, 替勃龙方案与芬吗通方案相比, 在治疗绝经期综合征方面, 保留时间显著增加。

关键词: 激素替代疗法, 绝经期综合征, 芬吗通, 替勃龙, 用药保留率

Abstract:

In the present study, we aimed to retrospectively analyze the medication prescriptions of menopausal women diagnosed with menopausal syndrome in our hospital from 2015 to 2018, and compare the retention rate of estrogen and progesterone sequential therapy and hormone continuous therapy in menopausal women. The rational drug management system of Ningbo Women and Children's hospital was used to screen the prescriptions of menopausal syndrome in 4 years. After the age, year included in the study, and prescription cost were adjusted, Kaplan-Meier regression analysis was performed to compare the prescription retention rates of the two drug regimens. The distribution of the two HRT regimens in the 4 years showed an increasing trend year by year, and the age groups of the two HRT regimens were mainly distributed between 41 and 60 years old, accounting for 97.1% and 87.06%, respectively. The cost distribution for the other two HRT regimens was approximately the same. Compared with the two HRT regimens, the drug retention rate of hormone continuous regimens was higher than that of hormone sequential regimens within 4 years. Kaplan-Meier regression analysis showed that the trend was significant (Tarone-Ware, Chi-square value=3.857, P = 0.050). This study found that the median retention time of HRT therapy in menopausal women in our hospital was about half a year, which was significantly lower than that reported in previous studies of 1 year or longer. In addition, the present study found that compared with Femoston, the tibolone regimen significantly increased retention time in the treatment of menopausal syndrome.

Key words: Hormone replacement therapy, Menopausal syndrome, Femoston, Tibolone, Drug retention rate

中图分类号:

R984

Supporting:

邵淑容, 邵小青, 陈漪. 激素序贯疗法和替勃龙在绝经期综合征妇女中的用药保留率调查[J]. 中国药学(英文版), 2020, 29(9): 649-655.

Shurong Shao, Xiaoqing Shao, Yi Chen. Study on drug retention in menopausal women with sequential hormone therapy and tibolone[J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(9): 649-655.

参考文献

[1] Brinton, R.D.; Yao, J.; Yin, F.; Mack, W.J.; Cadenas, E. Perimenopause as a neurological transition state. Nat. Rev. Endocrinol. 2015, 11, 393-405.

[2] Martini, J.; Knappe, S.; Garthus-Niegel, S.; Hoyer, J. Mental disorders in women: Natural course during premenstrual phases, peripartum period and perimenopause. Fortschr. Neurol. Psychiatr. 2016, 84, 432-449.

[3] Hansen, K.R.; Craig, L.B.; Zavy, M.T.; Klein, N.A.; Soules, M.R. Ovarian primordial and nongrowing follicle counts according to the Stages of Reproductive Aging Workshop (STRAW) staging system. Menopause. 2012, 19, 164-171.

[4] Soules, M.R.; Sherman, S.; Parrott, E.; Rebar, R.; Santoro, N.; Utian, W.; Woods, N. Executive summary: stages of reproductive aging workshop (STRAW). Climacteric. 2001, 4, 267-272.

[5] Pinkerton, J.V.; Aguirre, F.S.; Blake, J.; Cosman, F.; Hodis, H.N.; Hoffstetter, S.; Kaunitz, M.A.; Kingsberg, S.A.; Maki, P.M.; Manson, J.E.; Marchbanks, P.; Mcclung, M.R.; Nachtigall, L.E.; Nelson, L.M.; Pace, D.T.; Reid, R.L.; Sarrel, P.M. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017, 24, 728-753.

[6] Baber, R.J.; Panay, N.; Fenton, A.; IMS Writing Group. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016, 19, 109-150.

[7] Fahlén, M.; Fornander, T.; Johansson, H.; Johansson, U.; Rutqvist, L.E.; Wilking, N.; von Schoultz, E. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur. J. Cancer. 2013, 49, 52-59.

[8] Hahn, R.G. Compliance considerations with estrogen replacement: Withdrawal bleeding and other factors. Am. J. Obstet. Gynecol. 1989, 161, 1854-1858.

[9] Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1995, 273, 199-208.

[10] Chu, K.; Song, Y.; Chatooah, N.D.; Weng, Q.; Ying, Q.; Ma, L.; Qu, F.; Zhou, J. The use and discontinuation of hormone replacement therapy in women in South China. Climacteric. 2018, 21, 47-52.

[11] Liu, Y.; Zhang, Y.; Wang, Q.; Yang, W.; Chen, X.; Jing, S.; Zhao, L.; Zhang, C.; Wei, L.; Li, X.; Feng, W.; Zhong, D.; Fang, Y. Bioequivalence and safety study of letrozole tablet in healthy Chinese postmenopausal women volunteers. J. Chin. Pharm. Sci. 2013, 22, 190-196.

[12] Ettinger, B.; Li, D.K.; Klein, R. Continuation of post-menopausal hormone replacement therapy: comparison of cyclic versus continuous combined schedules. Menopause. 2018, 25, 1187-1190.

[13] Pinkerton, J.V.; Santoro, N. Compounded bioidentical hormone therapy: identifying use trends and knowledge gaps among US women. Menopause. 2015, 22, 926-936.

[14] Saeideh, Z.; Raziyeh, M.; Soghrat, F. Comparing the effects of continuous hormone replacement therapy and tibolone on the genital tract of menopausal women; a randomized controlled trial. J. Reprod. Infertil. 2010, 11, 183-187.

[15] Eiken, P.; Kolthoff, N. Compliance with long-term oral hormonal replacement therapy. Maturitas. 1995, 22, 97-103.

激素序贯疗法和替勃龙在绝经期综合征妇女中的用药保留率调查

Study on drug retention in menopausal women with sequential hormone therapy and tibolone

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics

本文评价